Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact Contact Barchart
Market:
Kalvista Pharmaceuticals Inc (KALV)
Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop Business Wire - Mon May 8, 5:30AM CDT

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced...

KALV : 10.34 (+1.57%)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Tue May 2, 5:30AM CDT

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate...

KALV : 10.34 (+1.57%)
KalVista Pharmaceuticals to Present Data at the 13th C1-inhibitor Deficiency & Angioedema Workshop Business Wire - Thu Apr 27, 5:30AM CDT

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced...

KALV : 10.34 (+1.57%)
Here's Why You Should Invest in Larimar (LRMR) Stock Now Zacks - Wed Apr 12, 11:07AM CDT

Here we discuss some reasons why investing in Larimar Therapeutics (LRMR) stock now is a good idea.

RETA : 93.93 (+2.01%)
KALV : 10.34 (+1.57%)
LRMR : 3.85 (+2.12%)
SRZN : 0.6450 (+3.35%)
Here's Why You Can Add KalVista (KALV) Stock to Your Portfolio Zacks - Wed Apr 12, 10:06AM CDT

Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now is a good idea.

NKTR : 0.6092 (-0.13%)
KALV : 10.34 (+1.57%)
LRMR : 3.85 (+2.12%)
SRZN : 0.6450 (+3.35%)
KalVista Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference Business Wire - Wed Apr 12, 5:30AM CDT

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced...

KALV : 10.34 (+1.57%)
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics Zacks - Tue Apr 11, 7:57AM CDT

Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics are part of the Zacks Industry Outlook article.

NKTR : 0.6092 (-0.13%)
CPRX : 12.06 (+4.51%)
KALV : 10.34 (+1.57%)
JNCE : 1.8800 (-2.59%)
LRMR : 3.85 (+2.12%)
5 Stocks to Buy as the Drug Industry Rebounds in 2023 Zacks - Mon Apr 10, 9:07AM CDT

Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one's portfolio.

CPRX : 12.06 (+4.51%)
NKTR : 0.6092 (-0.13%)
KALV : 10.34 (+1.57%)
JNCE : 1.8800 (-2.59%)
LRMR : 3.85 (+2.12%)
Wall Street Analysts Think KalVista Pharmaceuticals, Inc. (KALV) Could Surge 145.98%: Read This Before Placing a Bet Zacks - Tue Apr 4, 8:55AM CDT

The consensus price target hints at a 146% upside potential for KalVista Pharmaceuticals, Inc. (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend...

KALV : 10.34 (+1.57%)
KalVista Pharmaceuticals, Inc. (KALV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? Zacks - Wed Mar 22, 8:55AM CDT

KalVista Pharmaceuticals, Inc. (KALV) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions...

KALV : 10.34 (+1.57%)

Barchart Exclusives

Lean Hogs and the Rubber Band Disposition Barchart - Tue Jun 6, 3:40PM CDT
The lean hog market has turned into a classic Rubber Band Disposition, with commercial and noncommercial interests moving in different directions. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot